Loading organizations...
Hello Heart is a Bay Area, USA-based digital therapeutics provider that offers a clinically-based program for individuals to monitor and improve their heart health, primarily focusing on blood pressure management. The company sells its digital cardiovascular health programs to employers and health plans via B2B contracts, serving over 1.5 million members across more than 60 Fortune 500 clients. With over 100 employees, Hello Heart has raised a total of $120 million in funding, including a $70 million Series D round led by Stripes. Notable investors include Stripes, represented by Ron Shah, and BlueRun Ventures, with John Malloy and Cheryl Cheng. The platform aims to expand into cholesterol tracking and smart medication adherence, leveraging AI-driven insights for cardiovascular conditions. Hello Heart was founded in 2013 by Maayan Cohen and Ziv Meltzer.
Hello Heart has raised $139.3M across 6 funding rounds.
Hello Heart has raised $139.3M in total across 6 funding rounds.
Hello Heart has raised $139.3M across 6 funding rounds. Most recently, it raised $70.0M Series D in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2022 | $70M Series D | RON Shah | BlueRun Ventures, Conviction Partners, Hack VC, IVP, Maven Ventures, Menlo Ventures, Norwest Venture Partners, Nyca Partners, Outrun Ventures, Telescope Partners, Jason Henrichs, Peter Kight | Announced |
| May 1, 2021 | $45M Series C | IVP | BlueRun Ventures, Conviction Partners, Maven Ventures, Menlo Ventures, Peter Kight, Khosla Ventures, Resolute Ventures | Announced |
| Jul 1, 2019 | $12M Series B | BlueRun Ventures, Khosla Ventures | SV Angel, Tsvc Capital, Y Combinator, JOE Greenstein, Peter Kight | Announced |
| Mar 1, 2018 | $9M Series U | — | BlueRun Ventures, Peter Kight | Announced |
| Mar 27, 2015 | $1.3M Venture Round | Resolute Ventures | John Malloy, Noam Bardin, RAN Makavy | Announced |
| Mar 1, 2015 | $2M Series U | — | BlueRun Ventures, JOE Kraus, Recursive Ventures, Charlie Songhurst, Paul Holland, Peter Kight | Announced |
Hello Heart has raised $139.3M in total across 6 funding rounds.
Hello Heart's investors include Ron Shah, BlueRun Ventures, Conviction Partners, Hack VC, IVP, Maven Ventures, Menlo Ventures, Norwest Venture Partners, Nyca Partners, Outrun Ventures, Telescope Partners, Jason Henrichs.
Hello Heart is a digital therapeutics company exclusively focused on cardiovascular health, providing an FDA-cleared connected heart monitor, mobile app, and AI-powered tools to track and manage key heart health metrics like blood pressure, cholesterol, weight, activity, and medications.[1][2][5] It serves employers, health plans, and individuals at risk of heart disease—the leading cause of death in the US—by solving adherence challenges, delivering personalized coaching, and reducing preventable heart attacks and strokes through technology and behavioral science.[1][2][4] The platform has demonstrated clinical outcomes like 2x greater hypertension control and financial savings of $2,392 per participant annually, with over 1.6M users and strong engagement metrics.[3][4]
Growth momentum includes recent launches like Nia, the world's first AI heart health assistant for medication management (October 2025), and features like Dot-to-Dot for habit insights, backed by $138M+ in funding from Khosla Ventures, IVP, and Stripes.[1][6] As a leader in the American Heart Association’s Innovators’ Network and CVS Health offerings, Hello Heart drives high enrollment and retention via seamless digital tools.[2][4]
Founded in 2013, Hello Heart emerged from a vision to empower people against avoidable heart disease using mobile technology and behavioral science, starting with an early app for blood pressure tracking.[1][6] Co-founder and CEO Maayan Cohen has led its evolution, drawing from a team of clinicians, data scientists, and consumer software experts to build a comprehensive platform.[3][6] Early traction came from peer-reviewed studies showing drops in blood pressure, cholesterol, and weight among high-risk users, validating its approach amid rising demand for digital health solutions.[1][4]
Pivotal moments include scaling to whole-heart-health management, HITRUST certification for HIPAA compliance, and innovations like the Bluetooth pill box and AI features, transforming an "infancy" product into a market leader serving millions.[1][5][6]
Hello Heart rides the digital therapeutics wave, targeting heart disease as the #1 cause of death and costliest chronic condition amid rising healthcare digitization post-COVID.[2][4][6] Timing aligns with AI advancements enabling personalized medicine—Nia's launch capitalizes on this for adherence, a key blocker to outcomes, while employers seek ROI via reduced claims.[1][8] Market forces like aging populations, hypertension prevalence, and payer demands for evidence-based tools favor its validated model, influencing ecosystems through AHA and CVS integrations that standardize digital heart health.[2][4]
It shapes preventive care by proving tech can outperform traditional interventions, paving the way for AI in chronic disease management and employer wellness programs.[1][3]
Hello Heart's trajectory points to expanded AI innovations, like upcoming monitor features and pipeline tools, amplifying its mission to eradicate avoidable heart events.[1][5][6] Trends in AI companions, value-based care, and remote monitoring will propel growth, especially as payers prioritize cost-saving digital therapeutics. Its influence may evolve into a full-stack platform partnering deeper with pharma and providers, solidifying leadership in a $100B+ cardiovascular market—turning pocket companions into lifesavers for millions.[1][4] This builds on its foundation: empowering everyday heart health management through smarter, simpler tech.
